We identified 20 relevant studies. Ever OC use did not increase the future risk of MS (RR: 1.07, 95% CI: 0.92-1.24, I2: 66.5%). However, upon elimination of an outlier, a modest association was revealed (RR: 1.14, 95% CI: 1.00-1.30, I2: 51.8%). A pooled analysis of individuals with past use of OCs yielded no significant association with MS development. This observation was sustained following a leave-one-out test (RR: 1.23, 95% CI: 0.99-1.52, I2: 0%). Similarly, a current use of OCs did not put women at an increased MS risk. Duration of OC consumption appears not to influence MS risk either (5 years or more: 95% CI: 0.88-1.52, I2: 51.7%; 2 years or less: 95% CI: 0.95-1.25, I2: 0%). Finally, to assess the differential impact of OC types, a meta-analysis of progesterone-only OCs concluded insignificant MS future risk following consumption. A systematic literature review suggests that OCs are associated with lower expanded disability status scale and MS severity scores, though with no unanimous consensus on relapse rate reductions.